1. He, Cui-Hong, Qu, Yi. . [Research advances in neonatal hyperbilirubinemia and gene polymorphisms]. In Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 22, 280-284. doi:. https://pubmed.ncbi.nlm.nih.gov/32204767/
2. Sponholz, Christoph, Huse, Klaus, Kramer, Marcel, Platzer, Matthias, Bauer, Michael. . Gene polymorphisms in the heme degradation pathway and outcome of severe human sepsis. In Shock (Augusta, Ga.), 38, 459-65. doi:10.1097/SHK.0b013e31826ae951. https://pubmed.ncbi.nlm.nih.gov/23042203/
3. Mao, Haiyan, Xu, Yuan, Zhang, Zhengrong, Liu, Siping, Bo, Ping. 2020. Biliverdin Reductase A (BLVRA) Promotes Colorectal Cancer Cell Progression by Activating the Wnt/β-Catenin Signaling Pathway. In Cancer management and research, 12, 2697-2709. doi:10.2147/CMAR.S242531. https://pubmed.ncbi.nlm.nih.gov/32425592/
4. Chen, Xinju, Yang, Fangming, Zhang, Chuanlei, Chen, Xiaoqi, Zhao, Wenxia. 2024. BLVRA exerts its biological effects to induce malignant properties of hepatocellular carcinoma cells via Wnt/β-catenin pathway. In Journal of molecular histology, 55, 159-167. doi:10.1007/s10735-023-10179-w. https://pubmed.ncbi.nlm.nih.gov/38216836/
5. Jiang, Li, Wang, Xing, Wang, Yong, Chen, Xiaoyan. 2018. Quantitative proteomics reveals that miR-222 inhibits erythroid differentiation by targeting BLVRA and CRKL. In Cell biochemistry and function, 36, 95-105. doi:10.1002/cbf.3321. https://pubmed.ncbi.nlm.nih.gov/29368338/